ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the present study, we confirmed the necessity of DDX5 in the survival and proliferation of CML cells induced by BCR-ABL, and showed for the first time that therapy targeting DDX5 was effective for the treatment of CML that acquired drug resistance (Figure 8).